STEPHANIE ADAMS: Open Payments
NPI 1437805538 · PASCAGOULA, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$808 in 29 payments from 11 companies in 2025. Trend: 2023 $25 · 2024 $209 · 2025 $808
Food & beverage: $808
| Company | Payments | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC | 5 | $174 |
| AstraZeneca Pharmaceuticals LP | 8 | $159 |
| Verona Pharma, Inc. | 1 | $123 |
| Actelion Pharmaceuticals US, Inc. | 3 | $95 |
| United Therapeutics Corporation | 4 | $94 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $39 |
| GENZYME CORPORATION | 2 | $36 |
| ANI Pharmaceuticals, Inc. | 1 | $29 |
| Viatris Specialty LLC | 1 | $23 |
| Grifols USA, LLC | 1 | $20 |
Products named: WINREVAIR, Ohtuvayre, UPTRAVI, FASENRA, Tyvaso, TEZSPIRE, KEYTRUDA, DUPIXENT.
Industry payments across MS — which companies pay providers there.
